Roche’s Analyst Event at ASCO 2017
| Agenda | |
|---|---|
| The APHINITY study: | - Adjuvant Pertuzumab and Herceptin in Initial Therapy in patients with HER2-positive early breast cancer - Jose Baselga, MD, PhD., Physician-in-Chief and Chief Medical Officer, Memorial Hospital, MSKCC |
| Highlights late stage portfolio | - Sandra Horning, M.D., Chief Medical Officer and Head Global Product Development |
| Highlights early development | - Ira Mellman, gRED: Ph.D., Vice President, Cancer Immunology, Genentech - William Pao, pRED: M.D., Ph.D., Global Head Oncology Discovery and Translational Area, Roche |
| Oncology business update | - Daniel O’Day, CEO Roche Pharmaceuticals |
Please register to access the replay* *Privacy notice